Lorea Villanueva

837 total citations
22 papers, 572 citations indexed

About

Lorea Villanueva is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lorea Villanueva has authored 22 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 11 papers in Immunology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lorea Villanueva's work include Immunotherapy and Immune Responses (9 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Lorea Villanueva is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Lorea Villanueva collaborates with scholars based in Spain, United States and France. Lorea Villanueva's co-authors include Damiana Álvarez‐Errico, Manel Esteller, Pablo Sarobe, Juan José Lasarte, Marta Ruiz, Diana Llópiz, Leyre Silva, Bruno Sangro, Noëlia Casares and Teresa Lozano and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Lorea Villanueva

21 papers receiving 561 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lorea Villanueva Spain	13	275	261	238	70	65	22	572
Yanan Gao China	9	195 0.7×	199 0.8×	165 0.7×	100 1.4×	77 1.2×	11	505
Nourredine Himoudi United Kingdom	14	351 1.3×	164 0.6×	292 1.2×	50 0.7×	58 0.9×	18	599
Kijong Yi South Korea	10	160 0.6×	244 0.9×	204 0.9×	144 2.1×	37 0.6×	12	578
Michael Fehlings Singapore	10	442 1.6×	217 0.8×	370 1.6×	62 0.9×	36 0.6×	21	756
Johannes Laengle Austria	12	183 0.7×	181 0.7×	227 1.0×	61 0.9×	45 0.7×	25	505
Maria Teresa Rodia Italy	9	242 0.9×	103 0.4×	158 0.7×	44 0.6×	69 1.1×	12	451
Charlene Tow Singapore	4	340 1.2×	82 0.3×	326 1.4×	73 1.0×	56 0.9×	4	507
D. Carbone United States	9	261 0.9×	230 0.9×	231 1.0×	34 0.5×	65 1.0×	15	530
Patrick Roelli Switzerland	7	625 2.3×	221 0.8×	418 1.8×	43 0.6×	92 1.4×	7	852
Adel Samson United Kingdom	12	135 0.5×	155 0.6×	244 1.0×	52 0.7×	43 0.7×	30	422

Countries citing papers authored by Lorea Villanueva

Since Specialization

Citations

This map shows the geographic impact of Lorea Villanueva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorea Villanueva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorea Villanueva more than expected).

Fields of papers citing papers by Lorea Villanueva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorea Villanueva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorea Villanueva. The network helps show where Lorea Villanueva may publish in the future.

Co-authorship network of co-authors of Lorea Villanueva

This figure shows the co-authorship network connecting the top 25 collaborators of Lorea Villanueva. A scholar is included among the top collaborators of Lorea Villanueva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorea Villanueva. Lorea Villanueva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ciruelos, Eva, Tomás Pascual, Guillermo Villacampa, et al.. (2024). Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1008–1008. 4 indexed citations

Pernas, Sònia, Esther Sanfeliu, Guillermo Villacampa, et al.. (2024). Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy. npj Breast Cancer. 10(1). 101–101.

Santisteban, Marta, C. Saura Manich, Eva Ciruelos, et al.. (2024). 199P Adoptive PD1+ tumor-infiltrating lymphocyte therapy for metastatic TNBC: First results of the safety run-in phase of the TILS001 clinical trial. ESMO Open. 9. 103221–103221. 1 indexed citations

Chic, Núria, Eva Ciruelos, Cristina Saura, et al.. (2023). Abstract OT2-10-04: Treatment of advanced or metastatic triple-negative breast cancer with adoptive therapy of PD1+ tumor-infiltrating lymphocytes (TILS001 trial). Cancer Research. 83(5_Supplement). OT2–10. 2 indexed citations

Prat, Aleix, Tomás Pascual, Montserrat Muñoz-Mateu, et al.. (2023). Abstract P3-06-02: TATEN TRIAL (SOLTI-1716) Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC): interim analysis. Cancer Research. 83(5_Supplement). P3–6. 4 indexed citations

Ciruelos, Eva, Santiago González-Santiago, Santiago Escrivá-de-Romaní, et al.. (2023). 197P ATREZZO trial (SOLTI-1907): A phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC) - Interim analysis. ESMO Open. 8(1). 101386–101386. 1 indexed citations

Cejalvo, Juan Miguel, Claudette Falato, Lorea Villanueva, et al.. (2022). Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. Cancer Treatment Reviews. 106. 102392–102392. 18 indexed citations

Villacampa, Guillermo, Pablo Tolosa, Fernando Salvador, et al.. (2022). Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. 104. 102352–102352. 21 indexed citations

Arribillaga, Laura, Timothy S. Gomez, Teresa Lozano, et al.. (2020). Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens. Journal for ImmunoTherapy of Cancer. 8(1). e000704–e000704. 15 indexed citations

10.

Villanueva, Lorea, Damiana Álvarez‐Errico, & Manel Esteller. (2020). The Contribution of Epigenetics to Cancer Immunotherapy. Trends in Immunology. 41(8). 676–691. 155 indexed citations

11.

Silva, Leyre, Josune Egea, Lorea Villanueva, et al.. (2020). Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. Cancers. 12(11). 3397–3397. 23 indexed citations

12.

Llópiz, Diana, Marta Ruiz, Lorea Villanueva, et al.. (2018). The HDAC inhibitor belinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors in a murine hepatocellular carcinoma model. Journal of Hepatology. 68. S677–S677. 1 indexed citations

13.

Llópiz, Diana, Marta Ruiz, Lorea Villanueva, et al.. (2018). Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunology Immunotherapy. 68(3). 379–393. 116 indexed citations

14.

Llópiz, Diana, Marta Ruiz, Lorea Villanueva, et al.. (2016). IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Oncotarget. 8(2). 2659–2671. 40 indexed citations

15.

Zabaleta, Aintzane, Delia D’Avola, Diana Llópiz, et al.. (2015). Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. Molecular Therapy — Methods & Clinical Development. 2. 15006–15006. 16 indexed citations

16.

Lozano, Teresa, Lorea Villanueva, Marta Gorraiz, et al.. (2015). Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. The Journal of Immunology. 195(7). 3180–3189. 52 indexed citations

17.

Zabaleta, Aintzane, José Ignacio Riezu‐Boj, Esther Larrea, et al.. (2015). Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. Journal of Medical Virology. 88(5). 843–851. 3 indexed citations

18.

Arribillaga, Laura, Teresa Lozano, Francesc Rudilla, et al.. (2013). A Fusion Protein between Streptavidin and the Endogenous TLR4 Ligand EDA Targets Biotinylated Antigens to Dendritic Cells and Induces T Cell ResponsesIn Vivo. BioMed Research International. 2013. 1–9. 15 indexed citations

19.

Rudilla, Francesc, Catherine Fayolle, Noëlia Casares, et al.. (2012). Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. Vaccine. 30(18). 2848–2858. 22 indexed citations

20.

Mansilla, Cristina, Pedro Berraondo, Marta Martínez, et al.. (2011). Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. International Journal of Cancer. 131(3). 641–651. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact